TET3

Chr 2ADAR

tet methylcytosine dioxygenase 3

Also known as: BEFAHRS, hCG_40738

Enables RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; methyl-CpG binding activity; and zinc ion binding activity. Involved in positive regulation of transcription by RNA polymerase II and protein O-linked glycosylation. Predicted to be located in cytoplasm and male pronucleus. Predicted to be active in nucleus. Biomarker of esophagus squamous cell carcinoma. [provided by Alliance of Genome Resources, Jul 2025]

GeneReviewsOMIMResearchGenerating clinical summary…
LOFmechanismAD/ARLOEUF 0.091 OMIM phenotype
Clinical SummaryTET3
🧬
Gene-Disease Validity (ClinGen)
Beck-Fahrner syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

2 total gene-disease associations curated

Population Constraint (gnomAD)
Highly constrained gene — heterozygous loss-of-function variants are very rare in the population (pLI 1.00). One damaged copy is likely sufficient to cause disease.
📋
ClinVar Variants
58 unique Pathogenic / Likely Pathogenic· 319 VUS of 498 total submissions
📖
GeneReview available — TET3
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

LoF intolerant — likely haploinsufficient
LoF Constraint?
0.09LOEUF
pLI 1.000
Z-score 6.75
OE 0.02 (0.010.09)
Highly constrained

Among the most LoF-intolerant genes (~top 3%)

Missense Constraint?
2.88Z-score
OE missense 0.74 (0.700.79)
732 obs / 986.4 exp
Mild constraint

Moderately missense-constrained (top ~2.5%)

Observed / Expected Ratios?
LoF OE?0.02 (0.010.09)
00.351.4
Missense OE?0.74 (0.700.79)
00.61.4
Synonymous OE?1.06
01.21.6
LoF obs/exp: 1 / 55.1Missense obs/exp: 732 / 986.4Syn Z: -1.04
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
strongTET3-related DNA demethylation disorderLOFAD
strongTET3-related DNA demethylation disorderLOFAR

This gene — mechanism propensity

DN
0.15100th %ile
GOF
0.1699th %ile
LOF
0.88top 5%

The highest-scoring mechanism for this gene is loss-of-function (haploinsufficiency).

LOFprediction above median · 1 literature citation · 67% of P/LP variants are LoF · LOEUF 0.09

Literature Evidence

LOFTET3 is a methylcytosine dioxygenase that initiates DNA demethylation during early zygote formation, embryogenesis, and neuronal differentiation and is intolerant to haploinsufficiency in mice and humans.1

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312. Mechanism ranking also informed by gnomAD constraint, ClinVar, and ClinGen data.

References

  1. 1.PMID 31928709

ClinVar Variant Classifications

498 submitted variants in ClinVar

Classification Summary

Pathogenic13
Likely Pathogenic45
VUS319
Likely Benign74
Benign15
Conflicting15
13
Pathogenic
45
Likely Pathogenic
319
VUS
74
Likely Benign
15
Benign
15
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
9
1
3
0
13
Likely Pathogenic
30
14
1
0
45
VUS
9
285
22
3
319
Likely Benign
0
15
1
58
74
Benign
0
2
3
10
15
Conflicting
15
Total483173071481

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

10 pathogenic / likely-pathogenic (of 13) ClinVar copy-number / structural variants overlap TET3 — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

TET3 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →